Los 10 principales competidores de galencentre.org

cspi.org

CSPI supports policies aimed at keeping our food supply free of dangerous pathogens like Salmonella, E. coli, and Listeria. We led the fight for national legislation that promises safer produce, and whole and processed foods that are regulated by FDA. Now CSPI is working to bring the same modernizing concepts to the USDA’s oversight of meat and poultry safety.

guttmacher.org

Contraceptive information and services enable people to prevent unintended pregnancies and to plan and space wanted ones, thus promoting positive health, social and economic outcomes, and reproductive autonomy. The Guttmacher Institute’s analyses examine the need for robust domestic and international policies and programs administered by the US government, including the Title X national family planning program, Medicaid and international family planning assistance. Guttmacher also analyzes the impact of restrictive policies, such as the domestic and global gag rules.

who.int

The United Nations agency working to promote health, keep the world safe and serve the vulnerable.

nuffieldtrust.org.uk

With a general election approaching, the Nuffield Trust is publishing a series of briefings that challenge the NHS and social care manifesto commitments of UK political parties ahead of the electorate heading to the polls. The first in our series looks at NHS staffing, setting out a series of policy ‘tests’ that the next government must meet to address some of the longstanding issues to attracting, training and retaining the mix of staff needed to meet the needs of the population.

healthsystemtracker.org

This interactive tool provides up-to-date information on U.S. health spending by federal and local governments, private companies, and individuals. It was developed by KFF using data from the National Health Expenditure Accounts of the Centers for Medicare & Medicaid Services and will be updated annually with each data release. For help using this tool, check […]

bmcnephrol.biomedcentral.com

Non-melanoma skin cancer is a prevalent complication in renal transplant recipients due to long-term immunosuppressive therapy. Calcineurin inhibitors, such as tacrolimus and cyclosporine, are effective in preventing graft rejection; however, they significantly increase the risk of non-melanoma skin cancer through broad immunosuppressive and pro-oncogenic mechanisms. Belatacept, a selective co-stimulation blocker targeting the CD80/CD86-CD28 axis, has emerged as a mechanistically distinct alternative with potential benefits for oncologic and renal outcomes. The primary objective of this review is to examine the impact of belatacept-based immunosuppression on the incidence and progression of non-melanoma skin cancer in renal transplant recipients, compared to conventional Calcineurin inhibitors. Secondary objectives include evaluating the immunologic mechanisms underlying its distinct cancer risk profile, exploring combinatory regimens (particularly with mammalian target of rapamycin inhibitors), assessing metabolic and nephrotoxic implications, and addressing ethical and clinical considerations in switching stable patients from Calcineurin inhibitors to belatacept. Although retrospective studies suggest a lower incidence of non-melanoma skin cancer with belatacept, robust prospective data remain limited, and its use is associated with increased early rejection and post-transplant lymphoproliferative disorder risk, particularly in Epstein-Barr virus seronegative patients. Emerging molecular biomarkers and transcriptomic insights may facilitate the development of personalized immunosuppression strategies. Further randomized controlled trials and longitudinal studies are essential to clarify belatacept’s oncologic safety and optimize immunosuppressive protocols in high-risk transplant populations.

hhmi.org

The Nobel Assembly at the Karolinska Institute announced today that Michael Rosbash, a Howard Hughes Medical Institute (HHMI) investigator at Brandeis University, Jeffrey C. Hall of Brandeis University and Michael W. Young of the Rockefeller University are the recipients of the 2017 Nobel Prize in Physiology or Medicine for their discoveries of molecular mechanisms controlling the circadian rhythm.

fpf.org

With the support of grants from the Department of Energy and National Science Foundation, FPF is building a Research Coordination Network (RCN) for Privacy-Preserving Data Sharing and Analytics running through June 2027.